Completed PHASE2 INTERVENTIONAL NCT00278083

TNF-alpha Directed Therapy in Asthma

A Randomised, Double Blind, Placebo-controlled, Parallel Group Pilot Study to Determine the Effect of REMICADE on Safety, Efficacy and Biomarkers of Inflammation in Patients With Asthma Receiving Inhaled Corticosteroids

Sponsor: Imperial College London

Conditions Asthma

Interventions Asthma symptom scores diary Blood sampling Breath condensate Breath nitric oxide Lung function test for FEV1 Quality of life diary Sputum induction Study drug administration Tuberculin intradermal skin test Urinalysis

Updated 6 times since 2017 Last updated: Sep 13, 2023 Started: Oct 31, 2001 Completion: Apr 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Asthma, this trial is completed. The trial is conducted by Imperial College London and has accumulated 6 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Oct 2023 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Imperial College London

Data source: Imperial College London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom